JP2021512881A5 - - Google Patents

Info

Publication number
JP2021512881A5
JP2021512881A5 JP2020542273A JP2020542273A JP2021512881A5 JP 2021512881 A5 JP2021512881 A5 JP 2021512881A5 JP 2020542273 A JP2020542273 A JP 2020542273A JP 2020542273 A JP2020542273 A JP 2020542273A JP 2021512881 A5 JP2021512881 A5 JP 2021512881A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
concentration
present
range
Prior art date
Application number
JP2020542273A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019157340A5 (https=
JP2021512881A (ja
JP7407118B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/017294 external-priority patent/WO2019157340A1/en
Publication of JP2021512881A publication Critical patent/JP2021512881A/ja
Publication of JP2021512881A5 publication Critical patent/JP2021512881A5/ja
Publication of JPWO2019157340A5 publication Critical patent/JPWO2019157340A5/ja
Priority to JP2023145922A priority Critical patent/JP7627730B2/ja
Application granted granted Critical
Publication of JP7407118B2 publication Critical patent/JP7407118B2/ja
Priority to JP2025011263A priority patent/JP2025063316A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542273A 2018-02-08 2019-02-08 低ｐＨ医薬抗体製剤 Active JP7407118B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023145922A JP7627730B2 (ja) 2018-02-08 2023-09-08 低ｐＨ医薬抗体製剤
JP2025011263A JP2025063316A (ja) 2018-02-08 2025-01-27 低ｐＨ医薬抗体製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862628267P 2018-02-08 2018-02-08
US62/628,267 2018-02-08
US201962799577P 2019-01-31 2019-01-31
US62/799,577 2019-01-31
PCT/US2019/017294 WO2019157340A1 (en) 2018-02-08 2019-02-08 Low ph pharmaceutical antibody formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023145922A Division JP7627730B2 (ja) 2018-02-08 2023-09-08 低ｐＨ医薬抗体製剤

Publications (4)

Publication Number Publication Date
JP2021512881A JP2021512881A (ja) 2021-05-20
JP2021512881A5 true JP2021512881A5 (https=) 2022-02-16
JPWO2019157340A5 JPWO2019157340A5 (https=) 2022-02-16
JP7407118B2 JP7407118B2 (ja) 2023-12-28

Family

ID=65576686

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020542273A Active JP7407118B2 (ja) 2018-02-08 2019-02-08 低ｐＨ医薬抗体製剤
JP2023145922A Active JP7627730B2 (ja) 2018-02-08 2023-09-08 低ｐＨ医薬抗体製剤
JP2025011263A Pending JP2025063316A (ja) 2018-02-08 2025-01-27 低ｐＨ医薬抗体製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023145922A Active JP7627730B2 (ja) 2018-02-08 2023-09-08 低ｐＨ医薬抗体製剤
JP2025011263A Pending JP2025063316A (ja) 2018-02-08 2025-01-27 低ｐＨ医薬抗体製剤

Country Status (10)

Country Link
US (2) US20210047407A1 (https=)
EP (1) EP3749363A1 (https=)
JP (3) JP7407118B2 (https=)
AU (2) AU2019216759A1 (https=)
CA (1) CA3089906A1 (https=)
MA (1) MA51747A (https=)
MX (2) MX2020008219A (https=)
TW (2) TW202519264A (https=)
UY (1) UY38080A (https=)
WO (1) WO2019157340A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10227408B2 (en) 2015-02-19 2019-03-12 Compugen Ltd. Anti-PVRIG antibodies and methods of use
CN110088132B (zh) 2016-08-17 2020-10-27 康姆普根有限公司 抗tigit抗体，抗pvrig抗体及其组合
CN110214147A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 IL15/IL15Rα异源二聚体FC-融合蛋白
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
TN2019000225A1 (en) * 2017-02-02 2021-01-07 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
KR20210003813A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질
CA3097625A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
TW202519260A (zh) * 2018-07-02 2025-05-16 美商安進公司 抗steap1抗原結合蛋白
MA53333A (fr) * 2018-07-31 2021-11-03 Amgen Inc Formulations pharmaceutiques d'anticorps masqués
AU2019359475A1 (en) 2018-10-12 2021-05-20 Xencor, Inc. PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
CN114980922A (zh) * 2019-11-04 2022-08-30 康姆普根有限公司 抗pvrig抗体制剂和抗pd-1抗体的组合疗法
EP4097135A4 (en) * 2020-01-31 2024-07-03 Gensun Biopharma Inc. Bispecific t cell engagers
AU2021330845A1 (en) * 2020-08-24 2023-01-19 Amgen Inc. Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine
KR20250112314A (ko) * 2022-01-10 2025-07-23 페노믹 에이아이 항-콜라겐 삼중 나선 반복 함유 1(cthrc1) 항체 및 이를 사용하는 방법
WO2025042865A1 (en) 2023-08-21 2025-02-27 Amgen Research (Munich) Gmbh Methods for treating prostate cancer with bispecific antibodies binding steap1xcd3
WO2025042872A1 (en) 2023-08-21 2025-02-27 Amgen Research (Munich) Gmbh Combination therapy for treating prostate cancer
WO2025128807A1 (en) * 2023-12-13 2025-06-19 Amgen Inc. Radiolabeled compounds for the detection of steap1
WO2026039321A1 (en) 2024-08-12 2026-02-19 Amgen, Inc. Methods for treating prostate cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4396608A (en) * 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US7139665B2 (en) 2002-02-27 2006-11-21 California Institute Of Technology Computational method for designing enzymes for incorporation of non natural amino acids into proteins
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
EP1675620B1 (en) 2003-10-09 2019-05-08 Ambrx, Inc. Polymer derivatives
EP2327724A3 (en) 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20160355591A1 (en) * 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
JP2009534390A (ja) * 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
WO2008029908A1 (fr) * 2006-09-07 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Préparation pharmaceutique lyophilisée stable comprenant un anticorps
JP5577098B2 (ja) * 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
US9527926B2 (en) * 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
US8820052B2 (en) 2012-02-09 2014-09-02 Ford Global Technologies, Llc Liquid reductant system and method for operation of the liquid reductant system
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
US10858417B2 (en) * 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CA2902739C (en) 2013-03-15 2022-11-22 Xencor, Inc. Heterodimeric proteins
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
CN104474547A (zh) * 2015-01-07 2015-04-01 蓝佳堂生物医药（福建）有限公司 一种抗阴道感染免疫球蛋白复合抑菌剂
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
ITUB20152921A1 (it) 2015-08-06 2017-02-06 Lino Manfrotto Co S P A Supporto orientabile per apparecchiature video-fotografiche
JOP20170017B1 (ar) * 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
SI3468586T1 (sl) 2016-06-14 2025-01-31 Xencor, Inc. Bispecifična protitelesa za zaviralce kontrolnih točk

Similar Documents

Publication Publication Date Title
JP2021512881A5 (https=)
JPWO2019157340A5 (https=)
JP7080263B2 (ja) 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤
TWI860988B (zh) 低ph藥物製劑
TWI911431B (zh) 抗rsv單株抗體配製物
CN106999591B (zh) 一种抗pd-1抗体制剂及其在医药上的应用
JP2021504372A5 (https=)
FI3576788T3 (fi) Matalan ph-arvon omaava farmaseuttinen koostumus, joka käsittää t-soluihin sitoutuvia vasta-ainekonstrukteja
US12251474B2 (en) Process for lyophilized pharmaceutical formulations of a therapeutic protein
WO2020094122A1 (zh) 一种TGF-β受体融合蛋白药物组合物及其用途
JP2022036932A5 (https=)
JP2016104780A (ja) 抗体製剤
JP2016533335A5 (https=)
JP2016534052A5 (https=)
CN115916816B (zh) 抗血清白蛋白抗体
KR102399028B1 (ko) 이중-특이적 항원-결합 폴리펩티드
US20220378908A1 (en) Compositions and methods for minimizing protein loss at low protein concentrations
EP4190352B1 (en) Formulation of novel bispecific anti-cd3/cd20 polypeptide complex
KR20230058432A (ko) 약제학적 제형
US20260062469A1 (en) Compositions and methods for linear and conformational site-specific antibodies and methods of making the same
JP2026047374A (ja) 医薬製剤
KR20200012937A (ko) c-Met 항체 약물 접합체를 포함하는 약학 조성물 및 그의 용도
CN118382463A (zh) 一种包含抗CD79b抗体药物偶联物的药物组合物及其用途
US20230167176A1 (en) Pharmaceutical formulation
KR20230167968A (ko) 점도 감소 부형제 조성물 및 이를 포함하는 저점도 고농축 단백질 제형